Prospective Observational Multiple Myeloma Impact Study Prospective Multicenter Study To Measure The Impact Of Mmprofiler On Treatment Intention In Active Multiple Myeloma Patients Read more
Descartes-11 Consolidation Treatment In Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Read more
A Phase I Study to Evaluate the Pharmacokinetics and Safety of belantamab mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12) Read more
A Phase I Study to Evaluate the pharmacokinetics and safety of Belantamab Mafodotin Monotherapy in participants with Relapsed or Refractory Multiple Myeloma who have normal and varying degrees of impaired hepatic function (DREAMM 13) Read more
An Open-Label, Multicenter, Non-Randomized Phase 2 Study Of Pf-06863135 Monotherapy In Participants With Multiple Myeloma Who Are Refractory To At Least One Proteasome Inhibitor, One Immunomodulatory Drug And One Anti-Cd38 Antibody Read more
A Phase Ib Study Of SAR650984 (Anti-CD38 Mab) In Combination With Carfilzomib For The Treatment Of Relapsed Or Refractory Multiple Myeloma Read more
Phase II Trial Of SMO/AKT/NF2 Inhibitors In Progressive Meningiomas With SMO/AKT/NF2 Mutations Read more
A Randomized, Multicenter, Phase 2 Study Of DSP-7888 Dosing Emulsion In Combination With Bevacizumab Versus Bevacizumab Alone In Patients With Recurrent Or Progressive Glioblastoma Following Initial Therapy Read more
A Phase 3, Multicenter, Randomized, Open Label Study To Compare The Efficacy And Safety Of Bb2121 Versus Standard Triplet Regimens In Subjects With Relapsed And Refractory Multiple Myeloma Read more